Viviana Reyes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Viviana Reyes has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Devi Puerto
15 shared publicationsCarolina Wiesner
13 shared publications- Alba Lucia Combita
Instituto Nacional de Cancerologia
11 shared publications - Raúl Murillo
Grupo de Oncología PUJ-HUSI , Pontificia Universidad Javeriana, Facultad de Medicina, Carrera 7 #40-62, Bogotá, Colombia, 110211
10 shared publications Gustavo A. Hernandez-Suarez
8 shared publicationsMarcela Nuñez
8 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Prevalence of HPV vaccine types in the study population. Comparison between unvaccinated and vaccinates women ages 18 to 25 years according to doses (A) and to sexual debut (B).
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Prevalence of HPV vaccine types in the study population. Comparison between unvaccinated and vaccinates women ages 18 to 25 years according to doses (A) and to sexual debut (B).
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
In Colombia, the human papillomavirus (HPV) vaccine was launched in 2012 in the context of a school-based national vaccination program targeting girls ages 9 to 14 and offering catch-up vaccination for girls ages 14 to 17. In this study, we evaluated the program's impact on type-specific HPV infection by comparing HPV cervical prevalence among vaccinated and nonvaccinated women. This is a comparative cross-sectional study conducted 5 years after the quadrivalent HPV vaccination implementation in a sentinel Colombian City. This study included young women (18–25 years old) who had been vaccinated in the catch-up group and were attending universities and technical institutions, and women who attended primary health care facilities for Pap smear screening. The HPV prevalence of 1,287 unvaccinated women was compared with the prevalence of 1,986 vaccinated women. The prevalence of HPV16/18 infections was significantly lower in vaccinated compared with unvaccinated women (6.5% vs. 15.4%; P < 0.001), whereas for HPV6/11 infections, a decrease of 63.7% in vaccinated women (1.02% vs. 2.81%) was observed. The adjusted effectiveness to HPV16/18 was 61.4%; 95% CI, 54.3%–67.6%. However, the effectiveness against HPV16/18 was significantly higher among women vaccinated before their sexual debut 91.5%; 95% CI, 86.8–94.5, compared with effectiveness for vaccination after their sexual debut, 36.2%; 95% CI, 23.6–46.7. Five years after the introduction of HPV vaccines in Colombia, high effectiveness of HPV to prevent HPV16/18 infections is observed in the catch-up cohorts including virgin and sexually active women.Prevention Relevance:Monitoring HPV vaccines post-licensure plays an important role in assessing the progress of immunization programs, demonstrating the impact of vaccines on the population, and providing data for policy needs. In Colombia, HPV vaccines showed effectiveness when administered before start of sexual activity, and two doses are sufficient to achieve good protection.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
In Colombia, the human papillomavirus (HPV) vaccine was launched in 2012 in the context of a school-based national vaccination program targeting girls ages 9 to 14 and offering catch-up vaccination for girls ages 14 to 17. In this study, we evaluated the program's impact on type-specific HPV infection by comparing HPV cervical prevalence among vaccinated and nonvaccinated women. This is a comparative cross-sectional study conducted 5 years after the quadrivalent HPV vaccination implementation in a sentinel Colombian City. This study included young women (18–25 years old) who had been vaccinated in the catch-up group and were attending universities and technical institutions, and women who attended primary health care facilities for Pap smear screening. The HPV prevalence of 1,287 unvaccinated women was compared with the prevalence of 1,986 vaccinated women. The prevalence of HPV16/18 infections was significantly lower in vaccinated compared with unvaccinated women (6.5% vs. 15.4%; P < 0.001), whereas for HPV6/11 infections, a decrease of 63.7% in vaccinated women (1.02% vs. 2.81%) was observed. The adjusted effectiveness to HPV16/18 was 61.4%; 95% CI, 54.3%–67.6%. However, the effectiveness against HPV16/18 was significantly higher among women vaccinated before their sexual debut 91.5%; 95% CI, 86.8–94.5, compared with effectiveness for vaccination after their sexual debut, 36.2%; 95% CI, 23.6–46.7. Five years after the introduction of HPV vaccines in Colombia, high effectiveness of HPV to prevent HPV16/18 infections is observed in the catch-up cohorts including virgin and sexually active women.Prevention Relevance:Monitoring HPV vaccines post-licensure plays an important role in assessing the progress of immunization programs, demonstrating the impact of vaccines on the population, and providing data for policy needs. In Colombia, HPV vaccines showed effectiveness when administered before start of sexual activity, and two doses are sufficient to achieve good protection.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Characteristic of the study population. Comparison between vaccinated and unvaccinated women ages 18 to 25 years by sociodemographic and sexual behavior characteristics.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Characteristic of the study population. Comparison between vaccinated and unvaccinated women ages 18 to 25 years by sociodemographic and sexual behavior characteristics.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Vaccine effectiveness (VE) in vaccinated women aged 18–25 years: to different groups of HPV types (A) and to HPV16/18 according to sexual debut and number of doses (B). VEaAdjusted by using a propensity score analysis.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Vaccine effectiveness (VE) in vaccinated women aged 18–25 years: to different groups of HPV types (A) and to HPV16/18 according to sexual debut and number of doses (B). VEaAdjusted by using a propensity score analysis.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Prevalence of HPV types in the study population. Comparison between unvaccinated and vaccinates women ages 18 to 25 years. Adjusted by using a propensity score analysis.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Prevalence of HPV types in the study population. Comparison between unvaccinated and vaccinates women ages 18 to 25 years. Adjusted by using a propensity score analysis.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Prevalence of HR-HPV types in the study population. Comparison between unvaccinated and vaccinates women ages 18 to 25 years. Adjusted by using a propensity score analysis.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Prevalence of HR-HPV types in the study population. Comparison between unvaccinated and vaccinates women ages 18 to 25 years. Adjusted by using a propensity score analysis.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
HPV prevalence by Pap smear result. Comparison of cytological abnormalities between unvaccinated and vaccinates women ages 18 to 25 years (A) prevalence of HPV types in ASC-US and (B) L-SIL. Adjusted by using a propensity score analysis.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
HPV prevalence by Pap smear result. Comparison of cytological abnormalities between unvaccinated and vaccinates women ages 18 to 25 years (A) prevalence of HPV types in ASC-US and (B) L-SIL. Adjusted by using a propensity score analysis.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Detection and Genotyping of HPV DNA in a Group of Unvaccinated Young Women from Colombia: Baseline Measures Prior to Future Monitoring Program
In 2012, Colombia launched human papillomavirus (HPV) vaccination program for girls ages 9 to 12, and in 2013, the target age was expanded to 9 to 17 years. Monitoring the changes of HPV infection prevalence among young women has been proposed as an endpoint for early assessment of HPV vaccination programs. However, the data on HPV prevalence in young ages are very limited. The purpose of this study was to determine the prevalence of HPV infection and the distribution of genotypes in a group of nonvaccinated women ages 18 to 25 years old in three Colombian cities as baseline for the monitoring of the HPV national vaccination program. A total of 1,782 sexually active women were included. Cervical smear samples were collected to perform the Pap smear and HPV DNA detection using a Linear Array HPV assay. Of the 1,782 specimens analyzed, 60.3% were positive for any HPV type; 42.2% were positive for high-risk HPV (HR-HVP) types, and 44.4% for low-risk HPV (LR-HPV) types. Multiple and single infections were identified in 37.1% and 23.2% of samples, respectively. HR-HPV types -16, -52, and -51 were the most predominant with proportions of 11.3%, 7.92%, and 7.9%, correspondingly. The prevalence for HR-HPV 16/18 was 14.4%. HR-HPV prevalence in women with abnormal cytology (75.16%) was higher than in women with normal cytology (38.6%). In conclusion, a high prevalence of HR-HPV was observed among younger women. This HPV type-specific prevalence baseline may be used to monitor postvaccination longitudinal changes and to determine its impact on HPV-related disease incidence in Colombia population. Cancer Prev Res; 11(9); 581–92. ©2018 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Detection and Genotyping of HPV DNA in a Group of Unvaccinated Young Women from Colombia: Baseline Measures Prior to Future Monitoring Program
In 2012, Colombia launched human papillomavirus (HPV) vaccination program for girls ages 9 to 12, and in 2013, the target age was expanded to 9 to 17 years. Monitoring the changes of HPV infection prevalence among young women has been proposed as an endpoint for early assessment of HPV vaccination programs. However, the data on HPV prevalence in young ages are very limited. The purpose of this study was to determine the prevalence of HPV infection and the distribution of genotypes in a group of nonvaccinated women ages 18 to 25 years old in three Colombian cities as baseline for the monitoring of the HPV national vaccination program. A total of 1,782 sexually active women were included. Cervical smear samples were collected to perform the Pap smear and HPV DNA detection using a Linear Array HPV assay. Of the 1,782 specimens analyzed, 60.3% were positive for any HPV type; 42.2% were positive for high-risk HPV (HR-HVP) types, and 44.4% for low-risk HPV (LR-HPV) types. Multiple and single infections were identified in 37.1% and 23.2% of samples, respectively. HR-HPV types -16, -52, and -51 were the most predominant with proportions of 11.3%, 7.92%, and 7.9%, correspondingly. The prevalence for HR-HPV 16/18 was 14.4%. HR-HPV prevalence in women with abnormal cytology (75.16%) was higher than in women with normal cytology (38.6%). In conclusion, a high prevalence of HR-HPV was observed among younger women. This HPV type-specific prevalence baseline may be used to monitor postvaccination longitudinal changes and to determine its impact on HPV-related disease incidence in Colombia population. Cancer Prev Res; 11(9); 581–92. ©2018 AACR.